[{"id":"91d2c7e7-7017-45f1-805f-8e73462eafcd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01283945","created_at":"2021-01-18T05:12:34.871Z","updated_at":"2024-07-02T16:36:51.882Z","phase":"Phase 1/2","brief_title":"Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors","source_id_and_acronym":"NCT01283945","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" FGFR1 • KDR • VEGFA • FLT1","pipe":" | ","alterations":" FGFR1 amplification","tags":["FGFR1 • KDR • VEGFA • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lucitanib (E 3810)"],"overall_status":"Completed","enrollment":" Enrollment 134","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 05/04/2017","study_completion_date":" 05/04/2017","last_update_posted":"2020-01-03"},{"id":"443a9dde-c959-452a-9bb1-2c089607af50","acronym":"","url":"https://clinicaltrials.gov/study/NCT02747797","created_at":"2021-01-18T13:27:44.236Z","updated_at":"2024-07-02T16:37:08.340Z","phase":"Phase 2","brief_title":"Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations","source_id_and_acronym":"NCT02747797","lead_sponsor":"Teresa Helsten, MD","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lucitanib (E 3810)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2017","start_date":" 04/01/2017","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 04/01/2022","study_completion_date":" 04/01/2022","last_update_posted":"2018-08-02"}]